Cytokine 4-Plex C

Key features of the Simoa® C4PC Advantage PLUS Assay

• Ultra-sensitivity: Uncover critical insights into early biological and pathological processes from low-abundant cytokines at femtogram levels.
• Multiplex: Quantify four cytokines within a single assay with 25 µL input, conserving samples and resources.
• Full Automation: Enhance efficiency and reproducibility with walk-away automation on the HD-X.
• Scalability: Adapt the automated workflow for fast time-to-results or high-throughput, generating data from one 96-well plate in under 3 hours or up to 6 plates daily.
• Lot-to-Lot Consistency: Improve reliability for longitudinal and large-scale studies.

The target cytokines of Simoa® C4PC Advantage PLUS

IL-2: IL-2 is a potent pleiotropic cytokine primarily produced by CD4+ T cells upon antigen activation. IL-2 plays an important immune-modulating roles in resting and activated states of the immune system. It promotes the proliferation of cytotoxic effector cells that help the body fight against infections and eliminate cancer cells. It is also required for the expansion of Treg cells that are key for maintaining immune tolerance. IL-2 has therapeutic implications in immunotherapy, autoimmune disease and transplantation.

IL-6: IL-6 is a broad-acting cytokine that elicit both pro-inflammatory and anti-inflammatory outcomes

It is rapidly induced upon tissue damage or inflammation due to infections or injuries, stimulating acute phase immune reactions. IL-6 also plays a key role in adaptive immunity by promoting the differentiation of activated B cells into antibody-producing cells and naïve T cells into effector T cells. Dysregulated IL-6 has been implicated in autoimmune disease, chronic inflammatory disorders and cancers.

IL-8: IL-8 is a major pro-inflammatory mediator produced under inflammatory conditions by immune and other cell types. The most prominent role of IL-8 is attracting neutrophils to the sites of inflammation, while also contributes to promoting the proliferation and differentiation of monocytes, endothelial cells and angiogenesis.

IFN-γ: IFN-γ is a cytokine produced by activated CD4+ T cells, natural killer cells and macrophages. It is a critical mediator of immunity and inflammation with antiviral, antitumor and immunomodulatory functions. Its role in immune surveillance makes IFN-γ a potential therapeutic agent for cancer and certain infections. IFN-γ can contribute to autoimmunity and chronic inflammation under pathological conditions, presenting possibilities in treating these conditions by inhibiting IFN-γ.

Applications and Intended Use

The Simoa® C4PC Advantage PLUS is a digital immunoassay intended for the quantitative determination of IL-2, IL-6, IL-8, and IFN-γ concentrations in human serum and EDTA plasma samples.

Assay Specifications

• Compatible instruments: HD-X
• Analytical Lower Limit of Quantification (LLOQ): 0.019 – 0.7 pg/mL
• Lower Limit of Detection (LOD): 0.005 – 0.014 pg/mL
• Dynamic range: 0 – 320 pg/mL

(For detailed, analyte-specific specifications, please refer to the C4PC Advantage PLUS Datasheet)

Kit Contents

The assay kit includes all necessary reagents and controls to perform 96 tests.

Related Resources

Cytokine Biomarker Analysis with Simoa® for Neurology Research Publication Brief

Unraveling Inflammation in Neurological Disorders with Ultra-sensitive, Fully Automated Simoa® Cytokine Advantage PLUS App Note

Cytokine 4-Plex Advantage PLUS Product Flyer